Onkure Therapeutics Inc
OKUR2.170USD
-0.030-1.36%
시장 운영 시간 （ET）시세는 15분 지연됩니다
29.17M시가총액
손실P/E TTM
자세한 내용은 Onkure Therapeutics Inc 회사
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KαH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3Kα and has multiple programs designed to enable targeting of this key oncogene.
회사 정보
종목 코드 OKUR
회사 이름Onkure Therapeutics Inc
상장일Apr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
직원 수46
유형Ordinary Share
회계 연도 종료Apr 09
주소6707 Winchester Circle, Suite 400
도시BOULDER
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호80301
전화17203072892
웹사이트https://onkuretherapeutics.com/
종목 코드 OKUR
상장일Apr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
9.78K
+181.93%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dylan Hartley, Ph.D.
Dr. Dylan Hartley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ed T. Mathers ,
Ed T. Mathers ,
Independent Director
Independent Director
--
--
Ms. Valerie M. Jansen, M.D., Ph.D.
Ms. Valerie M. Jansen, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
9.78K
+181.93%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Mon, Jul 28
마지막 업데이트: Mon, Jul 28
주주
주주 유형
주주
주주
비율
Acorn Capital Advisors, LLC
22.14%
Citadel Advisors LLC
8.33%
Perceptive Advisors LLC
7.83%
Samsara BioCapital, LLC
6.43%
Shay Capital LLC
6.32%
Other
48.95%
주주
주주
비율
Acorn Capital Advisors, LLC
22.14%
Citadel Advisors LLC
8.33%
Perceptive Advisors LLC
7.83%
Samsara BioCapital, LLC
6.43%
Shay Capital LLC
6.32%
Other
48.95%
주주 유형
주주
비율
Hedge Fund
30.57%
Investment Advisor
30.02%
Venture Capital
15.38%
Private Equity
11.67%
Investment Advisor/Hedge Fund
10.55%
Individual Investor
1.66%
Research Firm
0.10%
Other
0.06%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
185
12.82M
99.94%
-1.09M
2025Q1
187
12.71M
99.28%
-1.05M
2024Q4
190
12.64M
105.50%
+4.22M
2024Q3
172
2.79M
546.32%
-1.40M
2024Q2
171
3.11M
93.03%
-1.12M
2024Q1
161
3.05M
91.28%
-864.58K
2023Q4
152
2.81M
85.98%
-309.72K
2023Q3
128
3.01M
91.00%
-83.83K
2023Q2
119
2.90M
88.58%
+621.98K
2023Q1
109
1.98M
78.98%
-170.10K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Acorn Capital Advisors, LLC
2.84M
22.14%
+1.40M
+97.24%
May 15, 2025
Citadel Advisors LLC
1.07M
8.33%
-6.21K
-0.58%
Mar 31, 2025
Perceptive Advisors LLC
1.00M
7.83%
--
--
Mar 31, 2025
Samsara BioCapital, LLC
824.15K
6.43%
--
--
Mar 31, 2025
Shay Capital LLC
810.21K
6.32%
+659.18K
+436.43%
May 15, 2025
The Vanguard Group, Inc.
706.73K
5.51%
--
--
Mar 31, 2025
Vestal Point Capital, LP
635.00K
4.95%
--
--
Mar 31, 2025
Deep Track Capital LP
523.99K
4.09%
--
--
Mar 31, 2025
StepStone Group LP
491.94K
3.84%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
478.55K
3.73%
--
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Global X Russell 2000 ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ALPS Medical Breakthroughs ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
더 보기
Invesco Dorsey Wright SmallCap Momentum ETF
비율0%
Global X Russell 2000 ETF
비율0%
Invesco Nasdaq Biotechnology ETF
비율0%
ProShares UltraPro Russell2000
비율0%
Dimensional US Core Equity 1 ETF
비율0%
ALPS Medical Breakthroughs ETF
비율0%
Proshares Ultra Russell 2000
비율0%
Global X Russell 2000 Covered Call ETF
비율0%
ProShares Ultra Nasdaq Biotechnology
비율0%
DFA Dimensional US Sustainability Core 1 ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
날짜
유형
비율
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
Oct 03, 2024
Merger
10<1
